Advertisement

Current Hematologic Malignancy Reports

, Volume 13, Issue 6, pp 446–454 | Cite as

Recent Updates on Chronic Myelomonocytic Leukemia

  • Sanam Loghavi
  • Joseph D. Khoury
Molecular Testing and Diagnostics (J Khoury, Section Editor)
  • 208 Downloads
Part of the following topical collections:
  1. Topical Collection on Molecular Testing and Diagnostics

Abstract

Purpose of Review

The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic models, and therapeutic approaches.

Recent Findings

The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification CMML. The clinical utility of the newly revised subclassification scheme is discussed. In addition, we provide an overview of the genetic changes involved in the pathogenesis of CMML and discuss the clinical utility of the more recently developed molecularly integrated prognostic models and their management and therapeutic implications. Finally, we provide an overview of the currently available treatment options for patients with CMML.

Summary

The classification of CMML as well as our understanding of its genomic landscape and optimal treatment approaches has advanced significantly over the past decade but remains in flux.

Keywords

Chronic myelomonocytic leukemia CMML MDS MPN Monocytosis ASXL1 SRSF2 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Supplementary material

11899_2018_475_MOESM1_ESM.pptx (16 kb)
Supplemental Figure 1 The frequency of somatic mutations in CMML, based on highest reported frequencies. Green: favorable prognostic impact; blue: intermediate prognostic impact; red: unfavorable prognostic impact; purple: no prognostic impact identified. (PPTX 16 kb)
11899_2018_475_MOESM2_ESM.pptx (81 kb)
Supplemental Figure 2 Prognostic factors included in various CMML-specific risk stratification systems. (abbreviations: MDAPS: MD Anderson Prognostic Score; BM: bone marrow; CPSS: CMML-specific prognostic scoring system; CMML; chronic myelomonocytic leukemia; WHO: World Health Organization; MD: myelodysplastic; MP: myeloproliferative; CPS-mol: CPSS molecular) (PPTX 81 kb)
11899_2018_475_MOESM3_ESM.pdf (84 kb)
Supplemental Table 1 List of currently active clinical trials for CMML (www. clinicaltrials.gov) (PDF 83 kb)

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Orazi A, Bennett JM, Germing U, Brunning R, Bain B, Cazzola M, et al. Chronic myelomonocytic leukemia. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber D, Hasserjian PH, Le Beau MM, Orazi A, Siebert R, editors. WHO classification of tumours of haematopoietic and lymhoid tissues. Lyon: International Agency for Research on Cancer; 2017. p. 82–6.Google Scholar
  2. 2.
    Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res. 2015;39(2):177–82.PubMedGoogle Scholar
  3. 3.
    Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML--dysplastic versus proliferative type. Leuk Res. 1998;22(10):871–8.PubMedGoogle Scholar
  4. 4.
    Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, et al. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood. 1984;63(3):634–8.PubMedGoogle Scholar
  5. 5.
    McCullough KB, Patnaik MM. Chronic myelomonocytic leukemia: a genetic and clinical update. Curr Hematol Malig Rep. 2015;10(3):292–302.PubMedGoogle Scholar
  6. 6.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451–8.PubMedGoogle Scholar
  7. 7.
    Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris LN, Stein H, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001. p. 49–52.Google Scholar
  8. 8.
    Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Thiele J. Chronic myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 76–9.Google Scholar
  9. 9.
    Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45(7):1311–8.PubMedGoogle Scholar
  10. 10.
    Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840–9.PubMedGoogle Scholar
  12. 12.
    Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375–83.PubMedGoogle Scholar
  13. 13.
    Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–15.PubMedGoogle Scholar
  14. 14.
    Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer. 2008;113(6):1351–61.PubMedPubMedCentralGoogle Scholar
  15. 15.
    •• Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 2016;128(10):1408–17. This study is important because it shows the value of incorporating mutation data in CMML risk stratification. Google Scholar
  16. 16.
    Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504–10.PubMedGoogle Scholar
  17. 17.
    •• Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, et al. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2018;2(15):1807–16. This study is important because it evaluates the revised WHO classification criteria for CMML in a large cohort of patients. Google Scholar
  18. 18.
    Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ, et al. Morphological evaluation of monocytes and their precursors. Haematologica. 2009;94(7):994–7.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Droin N, Jacquel A, Hendra JB, Racoeur C, Truntzer C, Pecqueur D, et al. Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood. 2010;115(1):78–88.PubMedGoogle Scholar
  20. 20.
    Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, et al. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017;44(12):1075–9.PubMedGoogle Scholar
  21. 21.
    Shen Q, Ouyang J, Tang G, Jabbour EJ, Garcia-Manero G, Routbort M, et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015;95(2):168–76.PubMedGoogle Scholar
  22. 22.
    Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125(23):3618–26.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, et al. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017;129(13):1881–3.PubMedGoogle Scholar
  24. 24.
    Patnaik MM, Timm MM, Vallapureddy R, Lasho TL, Ketterling RP, Gangat N, et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J. 2017;7(7):e584.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111–5.PubMedGoogle Scholar
  26. 26.
    •• Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 2014;89(8):813–8. This study is important because it re-evaluated the role of cytogenetic abnormalities in CMML and provides an improved cytogenetic risk stratification system for patients with CML. Google Scholar
  27. 27.
    Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–12.PubMedGoogle Scholar
  29. 29.
    Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, et al. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer J. 2018;8(1):12.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–36.PubMedGoogle Scholar
  32. 32.
    Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, et al. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014;89(5):499–504.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta MG, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513–21.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130(2):126–36.PubMedGoogle Scholar
  35. 35.
    Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92(1):56–61.PubMedGoogle Scholar
  37. 37.
    Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180–93.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun. 2015;6:7307.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23(8):1426–31.PubMedGoogle Scholar
  40. 40.
    Wang W, Routbort MJ, Loghavi S, Tang Z, Medeiros LJ, Wang SA. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res. 2018;70:97–9.PubMedGoogle Scholar
  41. 41.
    Patnaik MM, Padron E, Laborde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013.Google Scholar
  42. 42.
    Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, et al. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma. 2017;58(6):1488–93.PubMedGoogle Scholar
  43. 43.
    Patnaik MM, Lasho TL, Finke CM, Pardanani A, Tefferi A. Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. Am J Hematol. 2016;91(3):E12–4.PubMedGoogle Scholar
  44. 44.
    Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, et al. The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol. 2006;76(6):535–6.PubMedGoogle Scholar
  45. 45.
    Shah S, Loghavi S, Garcia-Manero G, Khoury JD. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol. 2014;7:26.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, et al. Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations. Am J Surg Pathol. 2018;42(6):799–806.PubMedGoogle Scholar
  47. 47.
    Loghavi S, Al-Ibraheemi A, Zuo Z, Garcia-Manero G, Yabe M, Wang SA, et al. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015;171(1):91–9.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, et al. Therapy related-chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018;93(1):65–73.PubMedGoogle Scholar
  49. 49.
    Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, et al. Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012;36(1):72–80.PubMedGoogle Scholar
  50. 50.
    Naresh KN, Pavlu J. Plasmacytoid dendritic cell nodules in bone marrow biopsies of chronic myelomonocytic leukemia. Am J Hematol. 2010;85(11):893.PubMedGoogle Scholar
  51. 51.
    Hu Z, Sun T. Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia. Blood. 2016;128(12):1664.PubMedGoogle Scholar
  52. 52.
    Loghavi S, Khoury JD. Disseminated blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;126(4):558.PubMedGoogle Scholar
  53. 53.
    Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055–61.PubMedGoogle Scholar
  54. 54.
    Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–46.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Pemmaraju N. Novel pathways and potential therapeutic strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. Curr Hematol Malig Rep. 2017;12(6):510–2.PubMedGoogle Scholar
  56. 56.
    Horny HP, Akin C, Arber DA, Peterson LC, Tefferi A, Metcalfe DD, et al. Mastocytosis. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber D, Hasserjian PH, Le Beau MM, Orazi A, Siebert R, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 62–9.Google Scholar
  57. 57.
    Patnaik MM, Rangit V, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, et al. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia. 2018;32:1850–6.PubMedGoogle Scholar
  58. 58.
    Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, et al. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018.Google Scholar
  59. 59.
    Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, et al. Eltrombopag use in patients with chronic myelomonocytic leukemia (CMML): a cautionary tale. Clin Lymphoma Myeloma Leuk. 2016;(16 Suppl):S64–6.Google Scholar
  60. 60.
    Solary E. Unplugging JAK/STAT in chronic myelomonocytic leukemia. Clin Cancer Res. 2016;22(15):3707–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations